Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Drug Discovery World

DECEMBER 20, 2022

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. Its Bio Studio program aims to foster the creation of new life science start-ups based on research from world-class scientists to benefit people and society.

Protein 52

Protein Life Science Antibody Business Development 52

Drug Discovery World

NOVEMBER 14, 2023

DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. The global arthritis monoclonal antibodies market grew from $49.44 billion in 2022 to $53.81

Antibody 59

Antibody Development FDA Approval Trials 59

Scienmag

NOVEMBER 4, 2020

Credit: Rayne Zaayman-Gallant/EMBL The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook onto the cell surface, the spike protein binds ACE2 using three finger-like protrusions, called the receptor binding domains (RBDs).

Scientist 65

Scientist Antibody Protein Medicine 65

The Pharma Data

FEBRUARY 12, 2022

The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. In the new work, they mapped at atomic scale the site, or “epitope,” to which the antibody binds on the SARS-Cov-2 spike protein.

Scientist 52

Scientist Antibody Protein Vaccination 52

Drug Discovery World

APRIL 15, 2024

Roxana McCloskey , Senior Global Marketing Manager, Protein Therapeutics, SCIEX explores how innovative analytical approaches can help improve stability for cell line development. MS provides precise information about PTM localisation and protein structure through assays such as subunit analysis and peptide mapping.

Development 59

Development Protein Antibody Production 59

Scienmag

APRIL 9, 2021

The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants Credit: Kelly Lab/Penn State A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

Antibody 93

Antibody Protein Scientist Research 93

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. The neutralizing activity of the sera developed by the scientists has been proved to be high against the P.1 1 (Gamma) and P.2

Antibody 52

Antibody Protein Scientist Clinical Trials 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   To what do you attribute your success?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

APRIL 25, 2024

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

Development 52

Development Bioassay Antibody Drug Delivery 52

The Pharma Data

SEPTEMBER 30, 2021

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

Protein 52

Protein Scientist Antibody Research 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884. Source link: [link].

Protein 52

Protein Vaccination Vaccine Antibody 52

Drug Discovery World

APRIL 18, 2024

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.

Development 52

Development Bioassay Antibody Drug Delivery 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Scientist 52

Scientist Immune Response Antibody Development 52

Scienmag

MAY 6, 2021

Inserting active-agent proteins into cancer cells using antibodies The ability of antibodies to recognize specific cancer cells is used in oncology to specifically target those cells with small active agents.

Protein 75

Protein Antibody Scientist Drugs 75

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Pharmaceutical Technology

NOVEMBER 29, 2022

For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours. Using chemokines, the scientists made the GBM tumours “hot”, making the chemokines aid in the immune cell migration to the tumour microenvironment.

Development 130

Development Research Antibody Engineer 130

Drug Discovery World

APRIL 11, 2023

Join industry-leading scientists from GSK, Oxford University, LifeArc, Alloy Therapeutics, Sanofi, and Carterra on April 19, 2023 in Cambridge, UK for this one-day, science-filled experience.

Drugs 52

Drugs Protein Antibody Scientist 52

Drug Discovery World

NOVEMBER 20, 2023

mRNA vaccines and antibody therapies in particular are promising areas that are already having significant impact across the healthcare industry, with enormous potential to address unmet medical needs. By improving access to accurate synthetic DNA, screening timelines can be reduced and a new generation of antibody therapeutics made possible.

DNA 69

DNA Engineer Antibody Gene 69

Pharmaceutical Technology

JULY 6, 2022

Scientists at the National Institutes of Health (NIH) unit National Institute of Neurological Disorders and Stroke (NINDS) have found that Covid-19-induced immune response could damage the blood vessels of the brain and may lead to short and long-term neurological symptoms. .

Immune Response 162

Immune Response Antibody Gene DNA 162

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. The vaccine produces antibodies that target the part of the surface protein of the influenza virus known to neutralize different influenza strains, the researchers said. MONDAY, Dec.

Scientist 52

Scientist Vaccination Vaccine Immune Response 52

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. To an extent, the challenge here lies in the nature of antibodies, says Contreras. Both drugs come with a high price tag.

Antibody 262

Antibody Drugs Protein Sales 262

Pharmaceutical Technology

MAY 19, 2023

The contentious battle is centred around two monoclonal antibodies that inhibit the protein PCSK9, which in turn lowers low-density lipoprotein (LDL) cholesterol levels. According to the company, such an approach is dangerous since companies could claim a whole genus of antibodies without discovering them.

Drugs 147

Drugs Antibody Protein Scientist 147

Drug Discovery World

APRIL 8, 2024

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Could you discuss the TCR T-cell target MAGE-A4 and what discoveries could be made by targeting this protein?

Antibody 64

Antibody Protein Development Engineer 64

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Drug Discovery World

MAY 25, 2023

Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . Broadly neutralising antibodies (bnAbs) are a rare type of antibody that can fight and protect against many different variants of a virus. .

Vaccination 52

Vaccination Vaccine Trials Antibody 52

Drug Discovery World

APRIL 11, 2024

By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies. As scientists we fully expect to spend long hours poring over data and puzzling over inconsistent results, but we are less ready to deal with the shifting sands of corporate priorities.

Research 59

Research Immune Response Antibody Medicine 59

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

World of DTC Marketing

APRIL 11, 2021

Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome. Antibody tests indicate you had a previous infection and that you may have some level of protection against the virus.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

The Pharma Data

MARCH 22, 2021

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days. The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance from the U.S.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52